|
2024
|
P/S
|
Pharmaceuticals; pharmaceutical preparations for diagnosing and treating neurodegenerative diseas... |
|
|
P/S
|
Pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; pharmaceutica... |
|
|
P/S
|
Pharmaceuticals Scientific research, pharmaceutical research, and medical research; technical con... |
|
|
Invention
|
Kinase inhibitors and uses thereof.
The present disclosure relates generally to compounds and co... |
|
|
Invention
|
Formulation, solid dosage form, and methods. The present disclosure relates generally to a granul... |
|
|
Invention
|
Anti-pilra antibodies, uses thereof, and related methods and reagents. e.g.,e.g., monkeys) withou... |
|
|
Invention
|
Compositions and methods for modulating tau expression. Provided herein are MAPT antisense oligon... |
|
|
Invention
|
Dual transporters and methods of use. Described are dual transporters and methods of making and u... |
|
|
Invention
|
Compounds, compositions, and methods.
The present disclosure relates generally to LRRK2 inhibito... |
|
|
Invention
|
Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin... |
|
|
Invention
|
Methods of engineering transferrin receptor binding polypeptides. Provided herein are polypeptide... |
|
|
Invention
|
Methods of increasing sialic acid levels in recombinant glycosylated proteins. Provided herein ar... |
|
|
Invention
|
Abeta-targeting proteins and methods of use. Described are Abeta-targeting proteins comprising an... |
|
|
Invention
|
Solid forms of 4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5-dihydro-2h-pyrido[3,4-f][1,4]oxazepine... |
|
|
Invention
|
Methods of engineering transferrin receptor binding polypeptides.
Provided herein are polypeptid... |
|
|
Invention
|
Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof.
Provided... |
|
2023
|
Invention
|
Methods and compositions related to engineered transferrin receptor‑binding molecules. e.g.,e.g.,... |
|
|
Invention
|
Cd98 heavy chain transgenic models. In some aspects, the present disclosure provides CD98hc polyp... |
|
|
Invention
|
Compounds, compositions, and methods. The present disclosure relates generally to small molecule ... |
|
|
Invention
|
Modulators of eukaryotic initiation factor 2.
The present disclosure relates generally to eukary... |
|
|
Invention
|
Processes and intermediates for the preparation of a pyrimidine aminopyrazole compound. N22HHNN 4... |
|
|
Invention
|
Solid and co-crystal forms of a pyrimidine triazole compound. The present disclosure relates to c... |
|
|
Invention
|
Process for the preparation of pyrimidinyl-4-aminopyrazole compounds.
The present disclosure rel... |
|
|
Invention
|
Engineered transferrin receptor binding polypeptides.
Provided herein are polypeptides that bind... |
|
|
Invention
|
Compounds, compositions and methods.
The present disclosure relates generally to compounds and c... |
|
|
Invention
|
Solid forms of 4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5- dihydro-2h-pyrido[3,4-f][l,4]oxazepin... |
|
|
Invention
|
Transferrin receptor binding molecule conjugates for delivery of oligonucleotides to cells. Provi... |
|
|
Invention
|
Process for preparing modulators of eukaryotic initiation factor 2b. The present disclosure relat... |
|
|
Invention
|
A quantitative pharmacological model of enzyme replacement therapy. This disclosure relates to sy... |
|
|
Invention
|
Transferrin receptor-binding domains and proteins comprising the same. Provided herein are transf... |
|
|
Invention
|
Fusion proteins comprising progranulin.
Provided herein are fusion proteins that comprise progra... |
|
|
Invention
|
Methods for treating brain glucose hypometabolism. Certain embodiments provide a method for treat... |
|
|
Invention
|
Monovalent anti-trem2 binding molecules and methods of use thereof. In one aspect, monovalent bin... |
|
|
Invention
|
Progranulin variants.
Provided herein are progranulin variants and fusion proteins that comprise... |
|
|
Invention
|
Affinity-based methods for using transferrin receptor-binding proteins.
Provided herein are meth... |
|
2022
|
Invention
|
Microglial cell morphometry.
Methods and systems described herein may allow for the classificati... |
|
|
Invention
|
Engineered anti-her2 bispecific proteins.
In one aspect, bispecific proteins having the ability ... |
|
|
Invention
|
Methods for the treatment of hunter syndrome.
Certain embodiments provide a method of providing ... |
|
|
Invention
|
Oligonucleotide conjugates targeted to the transferrin receptor.
Provided herein are conjugates ... |
|
|
Invention
|
Methods for treating and monitoring parkinson's disease.
The present disclosure relates to metho... |
|
|
Invention
|
Anti-transferrin receptor fusion proteins and methods of use thereof.
Certain embodiments provid... |
|
2021
|
Invention
|
Solid forms of a compound.
Forms of 2-(4-chlorophenoxy)-N-[3-[5-[cis-3-(trifluoromethoxy)cyclobu... |
|
|
Invention
|
Methods for treating and monitoring frontotemporal dementia.
The present disclosure provides met... |
|
|
P/S
|
pharmaceutical preparations for diagnosing and treating neurodegenerative diseases. scientific re... |
|
|
P/S
|
Pharmaceutical preparations for diagnosing and treating neurodegenerative diseases Scientific res... |
|
2019
|
P/S
|
scientific research, pharmaceutical research, medical research, technical consultation and produc... |
|
2017
|
P/S
|
pharmaceutical preparations for diagnosing and treating diseases of the central nervous system |
|
|
P/S
|
pharmaceutical preparations for diagnosing and treating neurodegenerative diseases |
|
2015
|
P/S
|
Pharmaceutical preparations for diagnosing and treating neurodegenerative diseases namely, centra... |
|
|
P/S
|
Pharmaceutical preparations for diagnosing and treating
neurodegenerative diseases. Scientific r... |
